David Charles Lubner
Insider Reports History
- Location
- Watertown, MA
- Signature
- /s/ Michelle Gilson, as Attorney-in-Fact
- All insider transactions
- Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date
Holdings reported by David Charles Lubner:
| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Arcellx, Inc. | Director | Common Stock | 21,659 | $1,624,425 | $75.00 | 20 Jan 2026 | Direct |
| Arcellx, Inc. | Director | Stock Option (right to buy) | 59,405 | 20 Jan 2026 | Direct | ||
| Dyne Therapeutics, Inc. | Director | Stock option (right to buy) | 35,000 | 30 May 2025 | Direct | ||
| Vor Biopharma Inc. | Director | Stock Option (Right to Buy) | 30,000 | 22 May 2025 | Direct | ||
| GLYCOMIMETICS INC | Director | Stock Option (Right to Buy) | 9,023 | 23 Jun 2025 | Direct | ||
| CARGO Therapeutics, Inc. | Director | Stock Option (Right to Buy) | 0 | 19 Aug 2025 | Direct | ||
| Gemini Therapeutics, Inc. /DE | Director | Stock Option (Right to Buy) | 0 | 04 Oct 2021 | Direct | ||
| POINT Biopharma Global Inc. | Director | Common Stock | 0 | $12.45 | 27 Dec 2023 | Direct | |
| POINT Biopharma Global Inc. | Director | Stock Option (Right to Buy) | 0 | 27 Dec 2023 | Direct |